An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder-Reference-Cited by-同舟云学术

An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder

Published:2019-01 Issue:1 Volume:39 Page:20-27
ISSN:1533-712X
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:J Clin Psychopharmacol

Author:

Simen Arthur,Whitlock Mark,Qiu Ruolun,Miceli Jeff,Zumpano Laura,Du Metz Michaele,Dua Pinky,Binneman Brendon

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference16 articles.

1. The epidemiology of generalized anxiety disorder;Psychiatr Clin North Am,2001

2. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis;Int Clin Psychopharmacol,2017

3. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders—Results from a European multicenter study;J Psychiatr Res,2017

4. Can long-term pharmacotherapy prevent relapses in generalized anxiety disorder? A systematic review;Clin Drug Investig,2017

5. Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers;Clin Neuropharmacol,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GABAergic implications in anxiety and related disorders;Biochemical and Biophysical Research Communications;2024-09

2. GABA System in Anxiety Disorders: A Review of Current and Novel GABAergic Drugs;Journal of Education, Humanities and Social Sciences;2023-11-26

3. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development;CNS Drugs;2023-08-21

4. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions;Expert Review of Neurotherapeutics;2023-05-15

5. Pronounced antiseizure activity of the subtype‐selective GABA _A positive allosteric modulator darigabat in a mouse model of drug‐resistant focal epilepsy;CNS Neuroscience & Therapeutics;2022-08-14